News | Intra-Aortic Balloon Pumps (IABP) | August 14, 2023

Datascope/Maquet/Getinge Recalls Cardiosave Hybrid and Rescue Intra-aortic Balloon Pumps (IABPs) for Unexpected Shutdowns

The FDA has announced that Datascope/Maquet/Getinge is recalling the Cardiosave Hybrid and Rescue Intra-aortic Balloon Pumps (IABPs) because they may shutdown unexpectedly due to electrical failures in the Power Management Board and/or Solenoid Board (Power Source Path). 

The FDA has announced that Datascope/Maquet/Getinge is recalling the Cardiosave Hybrid and Rescue Intra-aortic Balloon Pumps (IABPs) because they may shutdown unexpectedly due to electrical failures in the Power Management Board and/or Solenoid Board (Power Source Path).

August 14, 2023 — The FDA has announced that Datascope/Maquet/Getinge is recalling the Cardiosave Hybrid and Rescue Intra-aortic Balloon Pumps (IABPs) because they may shutdown unexpectedly due to electrical failures in the Power Management Board and/or Solenoid Board (Power Source Path). 

Using an affected pump may cause serious adverse health events, including unstable blood pressure, injury (for example: inadequate blood supply or a vital organ injury), and death. 

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death.. 

 

Recalled Product 

Recalled Product: 

  • Cardiosave Hybrid Intra-Aortic Balloon Pump (IABP) and Cardiosave Rescue Intra-Aortic Balloon Pump (IABP) 

Product Models: 

Distribution Dates: March 6, 2012 to May 19, 2023 

Devices Distributed in the U.S.: 4586 

Date Initiated by Firm: June 5, 2023 

 

Device Use 

The Cardiosave Hybrid Intra-Aortic Balloon Pump (IABP) and the Cardiosave Rescue IABP are electromechanical systems used to inflate and deflate intra-aortic balloons. These systems provide temporary support to the left ventricle through counter pulsation. Once the balloon is positioned in the aorta, the pump is set to work in synchrony with the electrocardiogram or arterial pressure waveform to make the balloon inflate and deflate at the right time during the cardiac cycle. 

Cardiosave Intra-Aortic Balloon Pumps are indicated for acute coronary syndrome, cardiac and non-cardiac surgery, or complications of heart failure in adults. They are used in health care facilities. 

 

Reason for Recall 

Datascope/Maquet/Getinge is recalling the Cardiosave Hybrid and Rescue Intra-aortic Balloon Pumps (IABPs) because they may shutdown unexpectedly due to electrical failures in the Power Management Board or Solenoid Board (Power Source Path). 

Using an affected pump may cause serious adverse health events, including unstable blood pressure, injury (for example: inadequate blood supply or a vital organ injury), and death. 

Datascope/Maquet/Getinge reported 26 complaints. There have been no reports of injuries, or death. 

 

Who May be Affected 

  • People who receive circulatory support using a Cardiosave Hybrid or Rescue IABP 
  • Health care personnel providing care that includes the Cardiosave Hybrid or Rescue IABP 

 

What to Do 

On June 5, 2023, Datascope/Maquet/Getinge sent all affected customers an Important Medical Device Advisory. 

The letter requested customers to: 

  • Ensure there is an alternative IABP available to continue therapy. 
  • Provide alternative hemodynamic support if there is no other means to continue counterpulsation therapy. 

 

Contact Information 

Customers with questions about this recall should contact their Datascope/Maquet/Getinge representative or call Datascope/Maquet/Getinge Technical Support at 1-888-943-8872, options 4, 2, 1, Monday through Friday, between the hours of 8:00 a.m. and 6:00 p.m. (Eastern Time). 

 

Additional Resources: 

Medical Device Recalls database 

 

How do I report a problem? 

Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program using an online form, regular mail, or FAX. 

 

Other recent FDA recalls: 

FDA Issues Update on Abbott Trifecta Valves: Potential Risk of Early Structural Valve Deterioration 

GE HealthCare Recalls TruSignal SpO2 Sensors for Issues That May Reduce Defibrillation Energy, Expose Patients to Unintended Voltage, or Give Inaccurate Readings 

Abiomed Recalls All Impella Left Sided Blood Pumps for Risk of Motor Damage After Contact with Transcatheter Aortic Valve Replacement (TAVR) Stent 

Abbott Recalls Amplatzer Steerable Delivery Sheath for Increased Risk of Air Embolism 


Related Content

News | FDA

April 16, 2026 — The U.S. Food and Drug Administration has granted 510(k) clearance to Royal Philips for its Philips ...

Home April 20, 2026
Home
News | FDA

April 7, 2026 —TRiCares SAS has received approval from the U.S. Food and Drug Administration (FDA) for an ...

Home April 09, 2026
Home
News | FDA

April 8, 2026 — Anumana, Inc. recently announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI ...

Home April 08, 2026
Home
News | FDA

March 24, 2026 — Anumana has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary ...

Home March 31, 2026
Home
News | FDA

March 25, 2026 — Royal Philips has received U.S. Food and Drug Administration (FDA) 510(k) clearance for EchoNavigator ...

Home March 27, 2026
Home
News | FDA

March 23, 2026 —Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for an expanded indication ...

Home March 24, 2026
Home
News | FDA

Feb. 27, 2026 — The U.S. Food and Drug Administration (FDA) has approved Abbott’s CardioMEMS Hero device — a pulmonary ...

Home February 27, 2026
Home
News | FDA

Feb. 17, 2026 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Retia Medical's Argos ...

Home February 17, 2026
Home
News | FDA

Jan. 13, 2026 – Innovative Health, Inc. has received its 50th clearance from FDA to reprocess single-use medical devices ...

Home January 15, 2026
Home
News | FDA

Jan. 12, 2026 — HeartLung Corp. has announced U.S. Food and Drug Administration (FDA) clearance of AI-CVD, its AI ...

Home January 12, 2026
Home
Subscribe Now